Clinical Trials Browser

Phase 3 × fluzoparib × Clear all

NCT06255392 2025-08-15

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Phase 3 Recruiting

Fludzoparib" and Anti-angiogenic

NCT03863860 2025-07-03

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Phase 3 Completed

Ovarian Neoplasms

NCT04691804 2024-12-31

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 3 Active not recruiting

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06539091 2024-08-06

Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer

Phase 3 Not yet recruiting

Carcinoma, Ovarian Epithelial

NCT04300114 2024-03-28

A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Phase 3 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3 Recruiting

Breast Neoplasms

NCT06188455 2024-01-03

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

Phase 3 Not yet recruiting

Ovarian Neoplasms

NCT04229615 2022-04-25

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Phase 3 Unknown

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04296370 2020-08-10

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Phase 3 Unknown

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation